Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising outcomes in early clinical studies. Ongoing inquiry https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/